Focus on EAS Innsbruck 2016: Keynote Lecture & Nobel Laureate Professor Brown
10 November 2015
A forward-looking scientific Programme to excite, inspire and inform!
The EAS 2016 Scientific Committee has created a programme featuring ground-breaking speakers in their respective fields. EAS 2016 Innsbruck welcomes a distinguished international faculty to share their forward-looking perspectives on the latest developments in basic research and clinical practice in atherosclerosis and cardiovascular disease. You can find details of the Plenary and Workshop sessions now on the Congress website, www.eas2016.kenes.com.
Abstract submission is now open. Submit your abstract by January 11, 2016 for the opportunity to present your findings at this prestigious international Congress.
Here, in a series of newsletters, we introduce members of the EAS 2016 Innsbruck faculty.
Keynote Lecture, Monday, May 30, 2016:
Professor Michael Brown, USA
The European Atherosclerosis Society is pleased to announce that the Keynote Lecture at EAS Congress 2016 will be given by Michael S. Brown, Paul J. Thomas Professor of Molecular Genetics and Director of the Jonsson Center for Molecular Genetics at University of Texas Southwestern, Dallas, USA.
Dr. Brown and his long-time colleague, Dr. Joseph L. Goldstein, are recognised as the discoverers of the low density lipoprotein (LDL) receptor, which controls the level of cholesterol in blood and in cells. Drs. Brown and Goldstein have received many awards for this work, including the U.S. National Medal of Science and the Nobel Prize for Medicine or Physiology in 1985.
Working together, Drs. Brown and Goldstein showed that familial hypercholesterolaemia is caused by genetic defects in the LDL receptor, which disrupt the normal regulation of cholesterol metabolism. Their studies led to the elucidation of the mechanism by which this receptor carries LDL particles into cells through coated pits and coated vesicles. These LDL receptor studies provided clear evidence for selective uptake of macromolecules into cells, giving rise to the concept of receptor-mediated endocytosis.
More recently, study of another genetic disease called Niemann-Pick C (NPC), has provided insights into how cholesterol is transported from one organelle to another, which underlie the consistency in cholesterol concentration in the plasma membrane. Extensive studies showed that both the NPC1 and NPC2 proteins have the capacity for binding LDL cholesterol. Whereas binding of cholesterol to NPC2 is rapid, occurring within minutes, binding to NPC1 is extremely slow, requiring several hours to reach equilibrium. However, this process can be accelerated when cholesterol is delivered by NPC2. Based on these findings, it was proposed that NPC2 extracts cholesterol from LDL in the lysosome and then transfers it to the N-terminal domain of membrane-bound NPC1 for insertion into the lysosomal membrane, currently being tested in the laboratory of Professor Brown.
The work of Drs. Brown and Goldstein has not only been the stimulus for new thinking about cholesterol homeostasis, but also has led to the development of new concepts in biology. Specifically, these include selective sorting of proteins within the plasma membrane, a prerequisite for receptor-mediated endocytosis; receptor-mediated endocytosis and receptor recycling; and, finally, the concept of feedback regulation of receptors.
Michael Brown graduated in 1962 from the College of Arts and Sciences of the University of Pennsylvania, with chemistry as his major subject, and subsequently obtained his M.D. degree in 1966 at the same university. He was an intern and resident at the Massachusetts General Hospital, where he met Joseph L. Goldstein, a fellow intern; the two established the friendship and mutual respect that led to their long-term scientific collaboration. Dr. Brown subsequently completed a postdoctoral fellowship at the National Institutes of Health, before moving to UT Southwestern, becoming Professor in 1976. The remainder of this story has been instrumental in changing how hypercholesterolaemia is managed, and paving the way for innovative new therapeutic agents targeting LDL cholesterol.